Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hypercoagulability in cancer

K B Green1, R L Silverstein

  • 1Division of Hematology-Oncology, Cornell University Medical College, New York, USA.

Hematology/Oncology Clinics of North America
|April 1, 1996
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Medical Review Officer Interpretation of Urine Drug Test Results.

Forensic science review·2015
Same author

Thrombospondin-1 restrains neutrophil granule serine protease function and regulates the innate immune response during Klebsiella pneumoniae infection.

Mucosal immunology·2014
Same author

Exosome poly-ubiquitin inhibits platelet activation, downregulates CD36 and inhibits pro-atherothombotic cellular functions.

Journal of thrombosis and haemostasis : JTH·2014
Same author

Thrombospondin-1 triggers macrophage IL-10 production and promotes resolution of experimental lung injury.

Mucosal immunology·2013
Same author

P2RY1 and P2RY12 polymorphisms and on-aspirin platelet reactivity in patients with coronary artery disease.

International journal of laboratory hematology·2012
Same author

The antiangiogenic effect of thrombospondin-2 is mediated by CD36 and modulated by histidine-rich glycoprotein.

Matrix biology : journal of the International Society for Matrix Biology·2005
Same journal

Palliative Therapy for Liver and Biliary Neoplasms.

Hematology/oncology clinics of North America·2026
Same journal

Ablative Therapies for Liver Tumors.

Hematology/oncology clinics of North America·2026
Same journal

Pathology of Liver and Biliary Neoplasms.

Hematology/oncology clinics of North America·2026
Same journal

Minimally Invasive Surgery for Liver and Biliary Tract Neoplasms.

Hematology/oncology clinics of North America·2026
Same journal

Surgical Considerations for Primary Liver Neoplasms.

Hematology/oncology clinics of North America·2026
Same journal

Systemic Therapy for Biliary and Liver Neoplasms: Chemotherapy and Immunotherapy.

Hematology/oncology clinics of North America·2026
See all related articles

Cancer patients often develop a hypercoagulable state, increasing the risk of blood clots and fibrin deposition. This review covers the causes, diagnosis, and treatment of thromboembolic disease in cancer.

Area of Science:

  • Oncology
  • Hematology
  • Pathology

Background:

  • Cancer is strongly associated with a hypercoagulable state, increasing thrombotic event risk.
  • Thromboembolic disease is a significant contributor to morbidity and mortality in cancer patients.
  • Fibrin deposition is observed in and around tumor sites, indicating a link between cancer and coagulation.

Purpose of the Study:

  • To discuss the complex pathogenesis of cancer-associated hypercoagulability.
  • To review the laboratory and clinical syndromes associated with this condition.
  • To provide recommendations for the diagnosis and treatment of thromboembolic disease in cancer.

Main Methods:

  • Review of clinical, biochemical, pathologic, and pharmacologic studies.
  • Analysis of the clinical manifestations of hypercoagulability in cancer.

Related Experiment Videos

  • Examination of fibrin deposition in tumor beds.

    • Main Results:

    • Cancer patients exhibit an increased incidence of intravascular thrombotic events.
    • Fibrin deposition is a common finding in the tumor microenvironment.
    • Thromboembolic disease represents a major cause of death in malignancy.

    Conclusions:

    • The link between cancer and hypercoagulability is well-established.
    • Understanding the pathogenesis is crucial for managing thromboembolic complications.
    • Effective diagnosis and treatment strategies are essential for improving outcomes in cancer patients.